Company: DNLI
Filing Date: 2025-12-10
Form Type: 8-K
Source: 0001628280-25-056363
Chunk: 1

Company: Denali Therapeutics Inc.
Filing Date: 2025-12-10
Form: 8-K
Item: Item 1.01
Chunk 1
---
326) (the “ Registration Statement”) and the related prospectus supplement and the accompanying prospectus, in each case filed with the Securities and Exchange Commission (the “ SEC”).

Each Pre-Funded Warrant will have an exercise price of $0.01 per share of Common Stock, subject to proportional adjustments in the event of stock splits or combinations or similar events, be immediately exercisable on the date of issuance and remain exercisable until exercised in full. The holders of Pre-Funded Warrants may not exercise a Pre-Funded Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The holders of Pre-Funded Warrants may increase or decrease such percentage not in excess of 19.99%, in the case of an increase, by providing at least 61 days’ prior notice to the Company.

The description of the Underwriting Agreement and the Pre-Funded Warrants set forth above is qualified in its entirety by reference to the Underwriting Agreement and the form of Pre-Funded Warrant, copies of which are filed as Exhibit 1.1 and Exhibit 4.1 hereto, respectively, and which are incorporated herein by reference.

A copy of the opinion of Wilson Sonsini Goodrich & Rosati, P. C. relating to the validity of the Shares, the Pre-Funded Warrants and the shares of Common Stock underlying the Pre-Funded Warrants is filed as Exhibit 5.1 hereto and is incorporated by reference into the Registration Statement.

Item 8.01 Other Events.